Paclitaxel 化学構造
分子量: 853.91

高品質保証

カスタマーフィードバック(2)

Quality Control & MSDS

製品説明

  • Compare Microtubule Associated Inhibitors
    Microtubule Associated製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 パクリタキセル(タキソール、Onxol、Nov-Onxol)は、人間の内皮細胞の0.1pMのIC50による微小管ポリマー安定剤です。
ターゲット Microtubule (human endothelial cells)
IC50 0.1 pM [1]
In vitro試験 Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
TE-15 M{HIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjrWXU1UUN3ME2wMlAxODJ6NzFOwG0> MXzTRW5ITVJ?
LC-2-ad NWjSZppKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PBN2lEPTB;MD6wNFA{OTdizszN MmPzV2FPT0WU
RL95-2 NYX3UmVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\1WpZKSzVyPUCuNFAxPjZ6IN88US=> M3P2VHNCVkeHUh?=
MZ1-PC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLMelZKSzVyPUCuNFAxPzJ7IN88US=> NH\sXXBUSU6JRWK=
TE-8 NX3HXHNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMECxNVch|ryP NIjKfI5USU6JRWK=
SW954 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXnWWp7UUN3ME2wMlAxOTF7IN88US=> MXHTRW5ITVJ?
TE-11 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvnTWM2OD1yLkCwNVI{KM7:TR?= NX65e4tDW0GQR1XS
PSN1 M3jYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrKe2VGUUN3ME2wMlAxOTNizszN NVjQUVVNW0GQR1XS
MOLT-4 NY[3NFM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTETWM2OD1yLkCwNVQ6KM7:TR?= NYTaZW9wW0GQR1XS
697 NVrLUYF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjWTWM2OD1yLkCwNVUh|ryP MmHHV2FPT0WU
ETK-1 NGjScZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\2TWM2OD1yLkCwNVUzKM7:TR?= NWm1PJF3W0GQR1XS
TE-10 NUT0e4xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5WFU1UUN3ME2wMlAxOTV2IN88US=> MmqxV2FPT0WU
HUTU-80 NEnSblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq2eItKSzVyPUCuNFAyPjhizszN M1iwTnNCVkeHUh?=
NTERA-S-cl-D1 M3\kWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTxSnlHUUN3ME2wMlAxOjB7IN88US=> NIW2SHBUSU6JRWK=
MFH-ino M17CXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HkfmlEPTB;MD6wNFI3QCEQvF2= MUnTRW5ITVJ?
IA-LM NU[0WWJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMECyPEDPxE1? MmjGV2FPT0WU
MC116 M3jUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;uOoJKSzVyPUCuNFAzQDlizszN NWn2XWc5W0GQR1XS
RKO MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7QWlZKSzVyPUCuNFAzQThizszN MlnpV2FPT0WU
MRK-nu-1 M4\ER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\3S2lEPTB;MD6wNFI6QSEQvF2= M2HZUnNCVkeHUh?=
VA-ES-BJ NIqxem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHBWHFLUUN3ME2wMlAxOyEQvF2= M3\ZVHNCVkeHUh?=
KALS-1 M2XzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfsZ4JKSzVyPUCuNFA{ODhizszN NFvGRotUSU6JRWK=
BB30-HNC MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LYXGlEPTB;MD6wNFMyPCEQvF2= NUftRZNyW0GQR1XS
ACN M33WSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjTfHZKSzVyPUCuNFA{OTZizszN NET2W|NUSU6JRWK=
TE-9 M{KxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ZPGlEPTB;MD6wNFMzPiEQvF2= MlHmV2FPT0WU
SIG-M5 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMECzNlch|ryP NXGzOllSW0GQR1XS
no-10 Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWySnVzUUN3ME2wMlAxOzZ{IN88US=> M1;aeXNCVkeHUh?=
EW-1 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfFTWM2OD1yLkCwN|cyKM7:TR?= NIPyN4lUSU6JRWK=
SK-LMS-1 M3j4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDvTWM2OD1yLkCwOFAyKM7:TR?= M2XSUXNCVkeHUh?=
GT3TKB NVO2eWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEC0N|Qh|ryP NGraeHVUSU6JRWK=
ES4 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3jW2lKSzVyPUCuNFA1PDlizszN M3XYbHNCVkeHUh?=
IMR-5 NYP3N5M{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofRTWM2OD1yLkCwOFUh|ryP MlHtV2FPT0WU
NCI-H1648 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEC0Olkh|ryP NES0WY5USU6JRWK=
MV-4-11 NGDjSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD4WIdoUUN3ME2wMlAxPDd3IN88US=> MWnTRW5ITVJ?
SK-UT-1 NFjpeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnYPYFKSzVyPUCuNFA1QCEQvF2= NIj3b5lUSU6JRWK=
NB13 NVjm[JhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfTXHNKSzVyPUCuNFA1QTFizszN MX\TRW5ITVJ?
DJM-1 M4rzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfKTWM2OD1yLkCwOVMh|ryP M1XPeXNCVkeHUh?=
ES8 NG\WNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[0TWM2OD1yLkCwOVM5KM7:TR?= Mk\KV2FPT0WU
TE-6 MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofvTWM2OD1yLkCwOVch|ryP MlLaV2FPT0WU
KS-1 NHXSSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfjfoNjUUN3ME2wMlAxPTh{IN88US=> M{fHfXNCVkeHUh?=
TE-1 M1naN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe2ZVNKSzVyPUCuNFA3ODZizszN M4HBfnNCVkeHUh?=
ATN-1 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m2c2lEPTB;MD6wNFYxQSEQvF2= M4my[XNCVkeHUh?=
A4-Fuk NWjNfmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XWVGlEPTB;MD6wNFYyOSEQvF2= NFXoVGFUSU6JRWK=
ALL-PO MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Vc2lEPTB;MD6wNFY{KM7:TR?= M1z0UHNCVkeHUh?=
BE-13 NXjYO4doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\PTWM2OD1yLkCwOlM3KM7:TR?= Mn7vV2FPT0WU
KM12 NV7iTW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jYUGlEPTB;MD6wNFY{PyEQvF2= M1yyeXNCVkeHUh?=
NOS-1 NYrNRYJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3PeIJnUUN3ME2wMlAxPjVizszN NYDXV2cyW0GQR1XS
SW962 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\JOo8xUUN3ME2wMlAxPjZ{IN88US=> M2\acnNCVkeHUh?=
OCUB-M M4jvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\QTWM2OD1yLkCwOlYzKM7:TR?= MmLaV2FPT0WU
NCI-H510A MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vPS2lEPTB;MD6wNFY3PSEQvF2= M1fCOHNCVkeHUh?=
EW-16 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXFR2pKSzVyPUCuNFA3QTRizszN NFTKU3BUSU6JRWK=
KGN NX71eGx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO1TWM2OD1yLkCwO|EzKM7:TR?= NH20WolUSU6JRWK=
LS-411N NVPwPFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEC3NVch|ryP Ml\tV2FPT0WU
Becker M{TGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfDTWM2OD1yLkCwO|Ih|ryP NGL5WpNUSU6JRWK=
HC-1 MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW4TWM2OD1yLkCwO|IyKM7:TR?= NGXHVIFUSU6JRWK=
CESS MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEC3N|ch|ryP M374enNCVkeHUh?=
KURAMOCHI NUfieop7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HpZWlEPTB;MD6wNFc1QCEQvF2= M1roOXNCVkeHUh?=
TGBC24TKB NITXVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITycWFKSzVyPUCuNFA4PTJizszN MYjTRW5ITVJ?
SW982 NEnzVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDGe5hRUUN3ME2wMlAxPzZ4IN88US=> NGWwPJJUSU6JRWK=
HCE-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTKNZFKUUN3ME2wMlAxPzZ5IN88US=> MofMV2FPT0WU
LOUCY NFL6XnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfPN286UUN3ME2wMlAxPzd3IN88US=> MmjRV2FPT0WU
8-MG-BA M2rkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDHWWdKSzVyPUCuNFA4QTZizszN M3Lke3NCVkeHUh?=
HT-144 NFnEOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fCU2lEPTB;MD6wNFgh|ryP NFLlUIdUSU6JRWK=
LXF-289 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\PcFZ1UUN3ME2wMlAxQDF6IN88US=> MWXTRW5ITVJ?
RS4-11 NIm5NXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEC4N|Yh|ryP MYjTRW5ITVJ?
DEL MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPX[5ZQUUN3ME2wMlAxQDR3IN88US=> NVrMcmZzW0GQR1XS
OCI-AML2 Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKwTWM2OD1yLkCwPFUzKM7:TR?= M1rNSHNCVkeHUh?=
CCRF-CEM Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KydGlEPTB;MD6wNFg4OSEQvF2= MVTTRW5ITVJ?
A388 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfJe4JqUUN3ME2wMlAxQDd2IN88US=> NVnrW|N1W0GQR1XS
KNS-42 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX5bmhKSzVyPUCuNFA5QTFizszN MnvXV2FPT0WU
OVCAR-4 NETiRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXjTWRnUUN3ME2wMlAxQTB2IN88US=> MVLTRW5ITVJ?
NCI-H1355 MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPzTWM2OD1yLkCwPVE1KM7:TR?= M3;C[nNCVkeHUh?=
BL-70 NXHCS5BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH2zXVFKSzVyPUCuNFA6OyEQvF2= MXXTRW5ITVJ?
BL-41 M3\kTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjNclRKSzVyPUCuNFA6OzRizszN NXj5Npg3W0GQR1XS
A101D NYC3PW9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;TXFJRUUN3ME2wMlAxQTZizszN MoDWV2FPT0WU
HL-60 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEC5OlYh|ryP MUTTRW5ITVJ?
COR-L279 NYHEPGxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEC5PVkh|ryP MlfVV2FPT0WU
NCI-SNU-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H4OWlEPTB;MD6wNVAxQCEQvF2= NEfYbWNUSU6JRWK=
Calu-6 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XobmlEPTB;MD6wNVAyOiEQvF2= NFnlPZNUSU6JRWK=
SR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jrTmlEPTB;MD6wNVAzPiEQvF2= MmT1V2FPT0WU
QIMR-WIL NH:0SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfaTWM2OD1yLkCxNFM{KM7:TR?= NFTRXJBUSU6JRWK=
LB647-SCLC NWrjU2JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMEGwOVEh|ryP NWjMd3hVW0GQR1XS
RPMI-8226 NITU[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7yVZo3UUN3ME2wMlAyOTB{IN88US=> MV7TRW5ITVJ?
SK-PN-DW MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlyyTWM2OD1yLkCxNVEzKM7:TR?= MUjTRW5ITVJ?
SF268 NGfu[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrNVYxbUUN3ME2wMlAyOTVzIN88US=> NH3uVplUSU6JRWK=
HD-MY-Z NUHpeJBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\hWItKSzVyPUCuNFEyPjNizszN M2TiWHNCVkeHUh?=
DOHH-2 MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TMRWlEPTB;MD6wNVIxOyEQvF2= Mn\PV2FPT0WU
SCC-3 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXSTWM2OD1yLkCxNlA1KM7:TR?= NGPzXGFUSU6JRWK=
ST486 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMEGyNFQh|ryP M3njOXNCVkeHUh?=
NALM-6 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y4e2lEPTB;MD6wNVIyPCEQvF2= NHfDXWVUSU6JRWK=
NCI-H1436 NWCzfm91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHjdnBKSzVyPUCuNFEzOzFizszN MmjvV2FPT0WU
KE-37 NWTJXJFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[5OGdKSzVyPUCuNFEzOzRizszN MUHTRW5ITVJ?
RPMI-8402 NVnUcW05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEGyOVYh|ryP NFHK[XNUSU6JRWK=
RXF393 M1e1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml74TWM2OD1yLkCxNlU4KM7:TR?= NIPFbHhUSU6JRWK=
KARPAS-45 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn5TWM2OD1yLkCxNlch|ryP NXq1cJljW0GQR1XS
HOP-62 NWDiVnA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL2XmJKSzVyPUCuNFEzPzZizszN MYDTRW5ITVJ?
ES1 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XtdmlEPTB;MD6wNVI5QCEQvF2= M1zGUnNCVkeHUh?=
L-363 NWnOUpBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEGzOVEh|ryP MVPTRW5ITVJ?
GI-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;CdW9KSzVyPUCuNFE{PzNizszN MYHTRW5ITVJ?
CTV-1 MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;RUoxDUUN3ME2wMlAyPDd6IN88US=> M1HISnNCVkeHUh?=
TE-5 M3LOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXyTWM2OD1yLkCxOFk3KM7:TR?= M36zS3NCVkeHUh?=
SNU-C2B NE\yeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W0UGlEPTB;MD6wNVQ6PiEQvF2= MmXYV2FPT0WU
K-562 M17ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHJW4t1UUN3ME2wMlAyPTF4IN88US=> NFfUR2pUSU6JRWK=
SNB75 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEG1OEDPxE1? NWKyTo05W0GQR1XS
MOLT-13 NXK1eJk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXlT5lKSzVyPUCuNFE3OzdizszN MWLTRW5ITVJ?
LS-123 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTRTWM2OD1yLkCxOlY1KM7:TR?= NF;DUYFUSU6JRWK=
NCI-SNU-5 NXXuSG9ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnqxTWM2OD1yLkCxO|AyKM7:TR?= MlqwV2FPT0WU
Daudi M2rMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPyTWM2OD1yLkCxO|A5KM7:TR?= MVrTRW5ITVJ?
A253 NH7zZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX71SnJ[UUN3ME2wMlAyPzN6IN88US=> NFjz[3JUSU6JRWK=
TGBC1TKB M2H4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HrNWlEPTB;MD6wNVc2OiEQvF2= NX\rdpV7W0GQR1XS
SJSA-1 M1fnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfETWM2OD1yLkCxO|Y4KM7:TR?= M4TS[HNCVkeHUh?=
NCCIT NX\wXXY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEG3Olkh|ryP NGWydmVUSU6JRWK=
NCI-H69 NID1SI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PPTmlEPTB;MD6wNVc4QCEQvF2= NUnmc3M5W0GQR1XS
SH-4 MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPpOnhrUUN3ME2wMlAyQDl3IN88US=> NHXjU2hUSU6JRWK=
HCC1187 M4Dv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf5NmVxUUN3ME2wMlAyQTJ2IN88US=> MmjjV2FPT0WU
HCC1599 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkmzTWM2OD1yLkCyNFIh|ryP Mkm4V2FPT0WU
ONS-76 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;DTWM2OD1yLkCyNFM3KM7:TR?= NFLvSllUSU6JRWK=
KU812 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEKwN|kh|ryP NFqyPYdUSU6JRWK=
ML-2 NYi2c|FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEKwOFch|ryP M4jTcnNCVkeHUh?=
HCE-T Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHqXXBKSzVyPUCuNFIxQTJizszN NIrFdJNUSU6JRWK=
NCI-H446 NVHleWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHhPXpSUUN3ME2wMlAzOTF{IN88US=> M{H4TXNCVkeHUh?=
RPMI-6666 NGrOOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIiyfmdKSzVyPUCuNFIyPDlizszN M1fscnNCVkeHUh?=
MOLT-16 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TSVGlEPTB;MD6wNlE2OyEQvF2= M3n6O3NCVkeHUh?=
JiyoyeP-2003 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEKxO|Yh|ryP M3vHcXNCVkeHUh?=
MHH-PREB-1 NIix[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiyb3RKSzVyPUCuNFIyQTFizszN M3LJTnNCVkeHUh?=
MC-CAR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHSUYY2UUN3ME2wMlAzOzJ4IN88US=> NYjaXlkyW0GQR1XS
BC-3 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3TTWM2OD1yLkCyN|Q1KM7:TR?= MkS4V2FPT0WU
KINGS-1 NV;hdIlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLxZZNrUUN3ME2wMlAzOzV3IN88US=> NH3DUHFUSU6JRWK=
PF-382 NXS4SZNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzWd|ZLUUN3ME2wMlAzOzd6IN88US=> NULPXWZFW0GQR1XS
J-RT3-T3-5 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEKzPFMh|ryP M4HxfHNCVkeHUh?=
SF539 NYD6TZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLFSWxKSzVyPUCuNFI1ODFizszN MWXTRW5ITVJ?
LB831-BLC Mo\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe0NoNKSzVyPUCuNFI1QDVizszN M4DjWHNCVkeHUh?=
DMS-114 NULUXnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXXTWM2OD1yLkCyOVAzKM7:TR?= NXLKS4kxW0GQR1XS
LB1047-RCC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PTeGlEPTB;MD6wNlUyKM7:TR?= MWTTRW5ITVJ?
LB771-HNC NFr0dmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEK1N|Qh|ryP NIDUeIhUSU6JRWK=
BB65-RCC NH:4TIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPBTWM2OD1yLkCyOVM1KM7:TR?= MV\TRW5ITVJ?
BV-173 MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMEK1OVQh|ryP MWnTRW5ITVJ?
ARH-77 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTHTWM2OD1yLkCyOlAyKM7:TR?= NYq4ZXZwW0GQR1XS
IST-MEL1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDwbnRHUUN3ME2wMlAzPjJ|IN88US=> M4HsZXNCVkeHUh?=
NB1 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDqV3U1UUN3ME2wMlAzPjh5IN88US=> MkXZV2FPT0WU
EoL-1-cell NX\PVHZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEK2PFgh|ryP NUXHWJZoW0GQR1XS
KY821 NEH5N4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\1cmlEPTB;MD6wNlY6PyEQvF2= M33SfnNCVkeHUh?=
CMK NXzy[ZVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\O[5VKSzVyPUCuNFI4OzRizszN NEGy[VVUSU6JRWK=
NCI-H2126 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;6RWZKSzVyPUCuNFI4PjhizszN MVrTRW5ITVJ?
NCI-H526 M1rENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH3fWJKSzVyPUCuNFI5QTFizszN M1noT3NCVkeHUh?=
COLO-684 NEXmbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrZTWM2OD1yLkCyPVA5KM7:TR?= NXu0V3hTW0GQR1XS
NCI-H747 M1P1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG1TWM2OD1yLkCyPVM{KM7:TR?= MX\TRW5ITVJ?
JAR M{e0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\UeGlEPTB;MD6wNlk1PiEQvF2= MWPTRW5ITVJ?
MEG-01 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHNTWM2OD1yLkCyPVc5KM7:TR?= M{npcHNCVkeHUh?=
MONO-MAC-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEOwNlMh|ryP Mnr2V2FPT0WU
IST-SL1 M2mzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEOwOFIh|ryP MUjTRW5ITVJ?
CPC-N NH;6TYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe2W5V5UUN3ME2wMlA{ODd7IN88US=> M4fJNHNCVkeHUh?=
NCI-H1963 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvDb2J1UUN3ME2wMlA{OTNzIN88US=> MYnTRW5ITVJ?
K052 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33rdmlEPTB;MD6wN|I1PyEQvF2= MmD3V2FPT0WU
KM-H2 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\kXXFKSzVyPUCuNFM{ODdizszN MYDTRW5ITVJ?
TE-12 MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjES5BKSzVyPUCuNFM{ODlizszN NXOxTGduW0GQR1XS
TK10 NV35XVZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD6NGpzUUN3ME2wMlA{OzV4IN88US=> M{K4eHNCVkeHUh?=
NMC-G1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfkTWM2OD1yLkCzOFUzKM7:TR?= NWPofphIW0GQR1XS
no-11 M3G3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEO0O|gh|ryP Mn2zV2FPT0WU
NCI-H524 M1X6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPuTWM2OD1yLkCzOVI6KM7:TR?= MWXTRW5ITVJ?
MHH-CALL-2 NXizRVBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;ETWM2OD1yLkCzOVYzKM7:TR?= MX;TRW5ITVJ?
GB-1 NHG2Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C3VWlEPTB;MD6wN|Yh|ryP MVLTRW5ITVJ?
OPM-2 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjaTWM2OD1yLkCzOlc{KM7:TR?= MV7TRW5ITVJ?
RH-1 NEjKXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrPc2lKSzVyPUCuNFM5OTlizszN NFrXVllUSU6JRWK=
NCI-H64 NVrIO3lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP2TodnUUN3ME2wMlA{QDV5IN88US=> MWjTRW5ITVJ?
EVSA-T NIjyU49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF71Xm9KSzVyPUCuNFM6OjNizszN NEDzR|hUSU6JRWK=
KARPAS-299 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvoOGFKSzVyPUCuNFM6QCEQvF2= NES5fIFUSU6JRWK=
MZ7-mel NYPsUZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC4cIhkUUN3ME2wMlA1ODRizszN MY\TRW5ITVJ?
LB373-MEL-D M2C1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMESxNFUh|ryP NEW2Z2lUSU6JRWK=
HEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LGcGlEPTB;MD6wOFE1KM7:TR?= M3LkTXNCVkeHUh?=
SW872 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMESyNUDPxE1? MonCV2FPT0WU
DU-4475 NF;ZdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvhUnFKSzVyPUCuNFQzPDRizszN NV75UG4zW0GQR1XS
IST-SL2 NUm1NnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDPTWM2OD1yLkC0Nlc2KM7:TR?= NG\RU|hUSU6JRWK=
NCI-H82 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDzTWM2OD1yLkC0N|A4KM7:TR?= NVLhSGpnW0GQR1XS
LC4-1 NES5XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMESzOVEh|ryP MWXTRW5ITVJ?
HDLM-2 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3r6emlEPTB;MD6wOFM6OiEQvF2= MnG2V2FPT0WU
MMAC-SF Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlyzTWM2OD1yLkC0OVM1KM7:TR?= M2\xPHNCVkeHUh?=
L-540 MnHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DPOWlEPTB;MD6wOFY{QSEQvF2= MkjPV2FPT0WU
MZ2-MEL NELmTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvFTWM2OD1yLkC0O|QzKM7:TR?= NVLzWIh{W0GQR1XS
LU-134-A M1nLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\OellKSzVyPUCuNFQ4PzNizszN MnewV2FPT0WU
UACC-257 M3HmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TJNWlEPTB;MD6wOFg1QSEQvF2= MVvTRW5ITVJ?
NCI-H1581 M1T5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXr[pNOUUN3ME2wMlA1QTV|IN88US=> M{XHNnNCVkeHUh?=
NB17 NGnpXWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThV5ZZUUN3ME2wMlA1QTd7IN88US=> MYXTRW5ITVJ?
SBC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPqTWM2OD1yLkC1NFQzKM7:TR?= NFrjRY9USU6JRWK=
TALL-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmr5TWM2OD1yLkC1NFQ2KM7:TR?= M3u2ZXNCVkeHUh?=
NCI-H1304 M2\lS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e2V2lEPTB;MD6wOVIxQCEQvF2= NVPQ[mdLW0GQR1XS
NEC8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUiyNZZMUUN3ME2wMlA2Ojh4IN88US=> MVrTRW5ITVJ?
CAL-148 M1PONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXWTWM2OD1yLkC1OFM6KM7:TR?= MoDtV2FPT0WU
CGTH-W-1 M1vhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEW0OFkh|ryP NEjn[4JUSU6JRWK=
NCI-H889 NHWwR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofaTWM2OD1yLkC1OVkzKM7:TR?= MoPkV2FPT0WU
GR-ST NH:3WnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\lVGlEPTB;MD6wOVYzOSEQvF2= MoPTV2FPT0WU
KARPAS-422 MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEW2OUDPxE1? NV24SJpXW0GQR1XS
RPMI-8866 M{K3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMEW3NVIh|ryP M{\mb3NCVkeHUh?=
SCLC-21H NWjGT4lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEW4PFQh|ryP NVHhRpQ3W0GQR1XS
COR-L88 NInaSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjh[mZVUUN3ME2wMlA2QTJ5IN88US=> NFe0OHlUSU6JRWK=
LU-139 NYDBcJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDpSHJKSzVyPUCuNFU6QDZizszN NIPLRm1USU6JRWK=
SF126 NU\4OYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnHdmxnUUN3ME2wMlA3OTN|IN88US=> MYDTRW5ITVJ?
NCI-H1882 M{S5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwME[0NlQh|ryP NULTU|c2W0GQR1XS
EW-24 NIH0U5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwME[0PFMh|ryP NFTvOFRUSU6JRWK=
CP67-MEL M1nLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\WS3ZRUUN3ME2wMlA3QDFizszN MXTTRW5ITVJ?
DG-75 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3qy[mlEPTB;MD6wOlg6QSEQvF2= MULTRW5ITVJ?
LOXIMVI NFrDNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX1NmVKSzVyPUCuNFcxOjhizszN Mn7aV2FPT0WU
HH NXO5SJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPnTWM2OD1yLkC3NVU4KM7:TR?= MUfTRW5ITVJ?
K5 NHf3coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEeyNlYh|ryP NV;WeHdtW0GQR1XS
EC-GI-10 M3zXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEeyOVch|ryP M2jjWHNCVkeHUh?=
SK-N-DZ MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GwemlEPTB;MD6wO|MxPyEQvF2= MWrTRW5ITVJ?
A3-KAW M4fib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP5eo5KUUN3ME2wMlA4OzVzIN88US=> NEK1fYFUSU6JRWK=
MLMA MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMEe0OlUh|ryP MWXTRW5ITVJ?
LB996-RCC MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;aZ5FHUUN3ME2wMlA4PzB5IN88US=> NEXPbnpUSU6JRWK=
OS-RC-2 NFzqO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzjTWM2OD1yLkC3O|Q5KM7:TR?= MXXTRW5ITVJ?
CTB-1 NFL5TG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEe4NUDPxE1? NEn5XVRUSU6JRWK=
IST-MES1 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLuV2J1UUN3ME2wMlA4QTF{IN88US=> M3mycXNCVkeHUh?=
LS-1034 NXXtPFY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLqTWM2OD1yLkC4NFM2KM7:TR?= Mn3yV2FPT0WU
HT NVjmO|ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\Wemk{UUN3ME2wMlA5ODh4IN88US=> NYKydlI4W0GQR1XS
NCI-H2141 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hk[WlEPTB;MD6wPFEh|ryP NUDKTllDW0GQR1XS
LB2518-MEL NGnkRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W1N2lEPTB;MD6wPFE1OSEQvF2= NY[3TINXW0GQR1XS
GI-ME-N NVnPbZFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ITWM2OD1yLkC4OFUzKM7:TR?= M3\wbnNCVkeHUh?=
TGW NH\kRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnGfGNKSzVyPUCuNFg3ODdizszN NF;ib3NUSU6JRWK=
SK-NEP-1 NGPhS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\1UoZkUUN3ME2wMlA5PjRzIN88US=> M{DJTnNCVkeHUh?=
NOMO-1 M2jLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEmyO|Uh|ryP M2H2NnNCVkeHUh?=
ES6 NW\ydYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLkTWM2OD1yLkC5OVg6KM7:TR?= NF\GVFVUSU6JRWK=
NCI-H209 M1m4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrLeWxKSzVyPUCuNFk4QDZizszN M{\zNnNCVkeHUh?=
GAK Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMUCxOkDPxE1? MXLTRW5ITVJ?
BC-1 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTuS2k3UUN3ME2wMlExOzZzIN88US=> MlnzV2FPT0WU
KLE MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLBcpRKSzVyPUCuNVA1PDNizszN NXLJ[pFbW0GQR1XS
EW-3 M3LV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDCTWM2OD1yLkGwPVgh|ryP MoTqV2FPT0WU
NKM-1 M{Todmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvuTWM2OD1yLkGxNUDPxE1? NWD0codrW0GQR1XS
D-336MG M1PhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13RRWlEPTB;MD6xNVI1PCEQvF2= NVfaeYZDW0GQR1XS
NB69 MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPxTWM2OD1yLkGxN|AyKM7:TR?= MWXTRW5ITVJ?
D-263MG Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHPTWM2OD1yLkGxO|EzKM7:TR?= Mn23V2FPT0WU
KP-N-YS NXe2XXFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwMUKyPVEh|ryP NID0d5dUSU6JRWK=
NCI-H1155 MoDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHScYdKSzVyPUCuNVI2PThizszN M2K2XHNCVkeHUh?=
BOKU MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDScmNKSzVyPUCuNVI2PzlizszN NFGzd41USU6JRWK=
LAMA-84 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD2[JZKSzVyPUCuNVI6QSEQvF2= MXfTRW5ITVJ?
Raji MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;WTWM2OD1yLkGzNVE4KM7:TR?= MXHTRW5ITVJ?
LU-65 NHSwTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDmOGFKSzVyPUCuNVM{ODdizszN MWTTRW5ITVJ?
NCI-H187 M13jTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMUO5NlQh|ryP M4fhcHNCVkeHUh?=
GCIY M{naWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTyW4FKSzVyPUCuNVQ6ODFizszN MWHTRW5ITVJ?
NCI-H2107 NUTLdohPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUWwPEDPxE1? MoPXV2FPT0WU
NCI-H1522 NUG5cWRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO2TWM2OD1yLkG1NlY3KM7:TR?= MVTTRW5ITVJ?
NB6 NUe4PIhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfzTWM2OD1yLkG1OlI{KM7:TR?= NIfScIVUSU6JRWK=
EM-2 NF23RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XXUWlEPTB;MD6xOVcxPiEQvF2= Mke1V2FPT0WU
HCC2218 M3\Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOzTWM2OD1yLkG1PVgh|ryP MoHwV2FPT0WU
NCI-H748 NWDTNW93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkOwTWM2OD1yLkG2N|c3KM7:TR?= M2rvcXNCVkeHUh?=
MS-1 M2nKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP2R5h5UUN3ME2wMlE3PTN5IN88US=> M4HVN3NCVkeHUh?=
NB5 NIPhbXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMU[1PVch|ryP NWjWbm5UW0GQR1XS
OMC-1 NGO2NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMU[2PFgh|ryP NXTSV|MzW0GQR1XS
NCI-H345 M{S1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC1TWM2OD1yLkG2PVI5KM7:TR?= M{nEV3NCVkeHUh?=
L-428 Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXENINKSzVyPUCuNVY6PDVizszN NWPqV25zW0GQR1XS
SCH M3i0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMUi2PFUh|ryP MX3TRW5ITVJ?
NCI-H1417 M1vxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X5SGlEPTB;MD6xPVIzPyEQvF2= MWjTRW5ITVJ?
COLO-320-HSR NHLpXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXa[IIyUUN3ME2wMlE6PTN{IN88US=> NGG2T5JUSU6JRWK=
BT-474 NW\yTHBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMkC4PVIh|ryP MojnV2FPT0WU
GDM-1 MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMkG5O|Eh|ryP NXj3flB2W0GQR1XS
NCI-H2196 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXJTW1oUUN3ME2wMlIzOjN3IN88US=> M4LJS3NCVkeHUh?=
KP-N-RT-BM-1 NGHUPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rtZmlEPTB;MD6yNlM1QSEQvF2= MY\TRW5ITVJ?
KNS-81-FD NFe5ZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUK2d5B3UUN3ME2wMlIzQTV6IN88US=> MUHTRW5ITVJ?
COLO-668 M{\ZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELVS5VKSzVyPUCuNlM3PzVizszN NELNNFZUSU6JRWK=
C2BBe1 M3r4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj5WIFbUUN3ME2wMlI3PzR5IN88US=> MWDTRW5ITVJ?
Ramos-2G6-4C10 NHjKdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMk[5OVQh|ryP NGWw[|lUSU6JRWK=
CAS-1 NH3BTodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LpUGlEPTB;MD6yO|A6PiEQvF2= MkDiV2FPT0WU
GOTO NWLYNFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfMOVVKSzVyPUCuNlc5QTRizszN NHXtUZlUSU6JRWK=
LP-1 NYfD[WZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMkiwOVch|ryP NHHQXJpUSU6JRWK=
NCI-SNU-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETCT5lKSzVyPUCuNlk1OjJizszN MljpV2FPT0WU
EB-3 NETZd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TSfWlEPTB;MD6yPVk4QSEQvF2= MYfTRW5ITVJ?
MHH-NB-11 M{m2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwM{C0NFIh|ryP MkWyV2FPT0WU
SK-N-FI NYGxenpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jPeWlEPTB;MD6zNVY6OiEQvF2= M4PPfnNCVkeHUh?=
HCC2157 NITo[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlX2TWM2OD1yLkOzPVE{KM7:TR?= NXPOeJJFW0GQR1XS
SIMA M3vMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\mdGZKSzVyPUCuN|Q2QDFizszN NHq0UYZUSU6JRWK=
MDA-MB-134-VI MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwM{[5Nlgh|ryP M1mxOXNCVkeHUh?=
NCI-H1694 NIDlNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7XfZNRUUN3ME2wMlM4KM7:TR?= MXfTRW5ITVJ?
EHEB MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwM{mwPFUh|ryP MkfqV2FPT0WU
U-266 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPtNpFEUUN3ME2wMlM6QDR4IN88US=> NHjKPXdUSU6JRWK=
LC-1F MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwNEO3OlUh|ryP M1jHNXNCVkeHUh?=
SHP-77 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPHTWM2OD1yLkS3PFU2KM7:TR?= MlP0V2FPT0WU
LS-513 NXj1UXZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDqTWM2OD1yLkS5N|A4KM7:TR?= NFfTS|RUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]
臨床試験 Paclitaxel has entered in a Phase III clinical trial for the treatment of tubular breast cancer stage II, mucinous breast cancer stage II, breast cancer female NOS and invasive ductal breast cancer.
特集

プロトコル (参考用のみ)

細胞アッセイ: [1]

細胞株 Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
濃度 0.1-100 pM
反応時間 72 hours
実験の流れ Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

動物実験: [4]

動物モデル Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
製剤 Control
投薬量 20 mg/kg
投与方法 Administered via i.v.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Paclitaxel SDF
分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管 2年-20℃
6月-80℃in solvent
別名 NSC 125973
溶解度 (25°C) * In vitro DMSO 171 mg/mL (200.25 mM)
エタノール 18 mg/mL (21.07 mM)
<1 mg/mL (<1 mM)
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-

カスタマーフィードバック (2)


Click to enlarge
Rating
Source , , ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck
Method Confocal Laser Scanning Microscopy Study
Cell Lines HeLa cells
Concentrations 5 μM
Incubation Time 24 h
Results From the figure, it was clear that interestingly α-TOS-Paclitaxel-NP induced highest PARP expression compared to α-TOS-CDDP-NP and α-TOS-Dox-NP.

Click to enlarge
Rating
Source RSC Adv , 2011, 1, 884-892. Paclitaxel purchased from Selleck
Method Microscope image
Cell Lines U937 cells
Concentrations
Incubation Time 24 h
Results The ODS-treated cells in Fig. b looked identical to the untreated cells in Fig. a with a similar rate of natural cell death of less than 3%. When Taxol microcrystals are added to the cell culture (the standard way that Taxol is released into biological systems), decreased cell proliferation rate, pronounced swelling and vacuolization are observed, as shown in Fig. c.

文献中の引用 (15)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related 微小管関連 阻害剤

  • TAI-1

    TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.

  • Docetaxel Trihydrate

    Docetaxel, an analog of taxol, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.

  • Combretastatin A4

    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.Phase 3.

  • FRAX597

    FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.

  • Docetaxel

    Docetaxel is an microtubule disassembly inhibitor with IC50 of a range of 0.31-100 ηM.

  • Vincristine

    Vincristine is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM.

  • Nocodazole

    Nocodazoleは反微小管薬品で、 ABL、 ABL(E255K) 、ABL(T315I)に作用すると 、 IC50 が それぞれ0.21 μM、 0.53 μM 、 0.64 μMになる。

  • Vinblastine

    Vinblastine inhibits microtubule formation and supresses nAChR activity with IC50 of 8.9 μM.

  • Vinorelbine Tartrate

    Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.

最近チェックしたアイテム

Tags: Paclitaxelを買う | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ